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ABSTRACT
A real-time assay for CpG-specific cytosine-C5
methyltransferase activity has been developed.
The assay applies a break light oligonucleotide in
which the methylation of an unmethylated 50-CG-30
site is enzymatically coupled to the development of
a fluorescent signal. This sensitive assay can
measure rates of DNA methylation down to
0.34±0.06fmol/s. The assay is reproducible, with a
coefficient of variation over six independent mea-
surements of 4.5%. Product concentration was
accurately measured from fluorescence signals
using a linear calibration curve, which achieved a
goodness of fit (R
2) above 0.98. The oligonucleotide
substrate contains three C5-methylated cytosine
residues and one unmethylated 50-CG-30 site.
Methylation yields an oligonucleotide containing
the optimal substrate for the restriction enzyme
GlaI. Cleavage of the fully methylated oligo-
nucleotide leads to separation of fluorophore from
quencher, giving a proportional increase in fluo-
rescence. This method has been used to assay
activity of DNMT1, the principle maintenance
methyltransferase in human cells, and for the
kinetic characterization of the bacterial cytosine-
C5 methyltransferase M.SssI. The assay has been
shown to be suitable for the real-time monitoring
of DNMT1 activity in a high-throughput format,
with low background signal and the ability to
obtain linear rates of methylation over long
periods, making this a promising method of
high-throughput screening for inhibitors.
INTRODUCTION
The methylation of bases in the DNA of both prokaryotic
and eukaryotic genomes is the most common of enzymatic
base modiﬁcations (1). Three methylated bases are known
to occur in nature: N6-methyladenine (2), which
is found in bacteria and eukaryotes, N4-methylcytosine
(3), a minor component of bacterial DNA and
C5-methylcytosine (4), which is the most prevalent of
the known DNA modiﬁcations (5). The methyl group is
transferred enzymatically by DNA methyltransferases,
which use S-adenosylmethionine (AdoMet) as the
methyl donor. In bacteria, adenine-N6 methylation plays
a key role in mismatch repair (6), the control of gene
expression (7) and regulation of the cell cycle (8). In
metazoa, cytosine-C5 methylation is the only DNA
methylation which has been identiﬁed (9). Cytosine
methylation in higher eukaryotes is critical for the
control of cellular diﬀerentiation and development (10),
gene expression, where promoter methylation leads to
gene repression (11) and has also been implicated in
X-chromosome silencing (12). Cytosine-C5 methylation
mainly occurs within the sequence 50-CG-30 and within a
higher eukaryotic genome, typically 60–90% of cytosine
residues within this sequence are methylated (13). The
process of cytosine-C5 methylation is of medical interest
as variation from normal methylation patterns and the
corresponding alteration in gene expression has been
shown to be involved in the development of many condi-
tions, such as fragile X chromosome (14) and cancer (15).
Cancer development has been linked to hypermethylation
of CG-rich sequences (CpG islands), which occur within
the promoter regions of tumour suppressor genes, which,
in turn, causes gene repression (16). In mammals, three
higher-activity cytosine-C5 methyltransferases have been
identiﬁed: DNA methyltransferase 1 (DNMT1) (17),
DNMT3a and DNMT3b (18). A fourth enzyme,
DNMT2, has been observed to have a very low
methyltransferase activity in vitro (19).
DNMT1 is the most abundant methyltransferase in
mammalian cells. It is responsible for the maintenance
of methylation patterns in DNA (20) and as such shows
a preference for hemimethylated over unmethylated
substrates (21,22). DNMT1 has been shown to interact
with a wide range of proteins (23). Examples include
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DNMT1 to replication sites (24) and UHRF1
(ubiquitin-like, containing PHD and RING ﬁnger
domains 1), which is thought to target DNMT1 to
hemimethylated DNA (25). In cancer cell lines, depletion
of DNMT1 with anti-sense inhibitors has been linked with
the demethylation of tumour suppressor gene promoters
and reactivation of expression (26), indicating that
DNMT1 is responsible for this hypermethylation. These
results imply that DNMT1 inhibitors may prove to be
eﬀective anti-cancer drugs (27,28) and an example of
their application in cancer treatment is the DNMT1 inhib-
itor 5-azacytidine (Vidaza), which has been approved for
use in the treatment of myelodysplastic syndrome (29).
The ability to assay DNMT1 activity is essential to inves-
tigate its substrate speciﬁcity in terms of DNA sequence
and methylation state, to gain a greater understanding of
the allosteric control of its C-terminal catalytic domain by
the N-terminal regulatory domain (24,30), the eﬀect of the
wide range of proteins with which it is known to interact
with upon activity (23) and screening compound libraries
for potential inhibitors.
A commonly adopted approach to the kinetic analysis
of methyltransferase activity has used the transfer of a
3H
labelled methyl group from AdoMet to an oligonucleotide
substrate, with the degree of methylation quantiﬁed
by ﬁlter binding and scintillation counting (31,32).
This assay has been widely applied, including in the
analysis of DNMT1 activity (22), but this assay format
is labour intensive and is neither continuous nor appro-
priate for high-throughput screening. Cytosine-C5
methyltransferase activity has also been measured using
radiolabelled AdoMet in an alternative format in which
the oligonucleotide substrate was immobilized onto a
microplate using a biotin–avidin interaction (33).
The oligonucleotide was then cleaved from the plate and
scintillation counted. This assay provides the advantages
of potential for high-throughput and lower background
radioactivity than the ﬁlter-binding assay, but involves
multiple processes and does not yield real time kinetic
data. Alternative assay formats have been described
that measure the turnover of AdoMet to S-adenosylho-
mocysteine via a colorimetric (34) or ﬂuorescence
polarization antibody binding assay (35), respectively.
However, neither of these are suitable for continuous mea-
surement as the colorimetric assay involves several steps
and the polarization assay is lengthy and limits the
AdoMet concentration to no higher than 1mM.
The therapeutic potential of DNMT1 inhibitors has
provided the drive to develop a new assay suitable for
the kinetic analysis of cytosine-C5 methyltransferase
activity in a format applicable to high-throughput screen-
ing. Recently, two ﬂuorescence-based methyltransferase
assays have been developed. The ﬁrst general strategy
relies upon protection (by methylation) of a restriction
endonuclease cleavage site, coupled to an enzyme-linked
immunosorbent assay (ELISA) detection format (36). This
method is compatible with high-throughput screening and
is suitable for assaying the activity of a broad range of
methyltransferases, but it requires a series of lengthy pro-
cesses and does not provide real-time data. An alternative
approach couples the use of a methylation sensitive
restriction endonuclease with the protection or promotion
of cleavage of a break light oligonucleotide. A molecular
break light is a single-stranded self-complementary
oligonucleotide, which spontaneously forms a hairpin
loop structure with a ﬂuorophore at the 50 terminus and
a quencher dye at the 30 terminus (37). In this structure,
the ﬂuorophore and quencher are locked close in space,
promoting eﬃcient quenching. Cleavage of the stem leads
to the melting of the short cleaved sequence and separa-
tion of ﬂuorophore and quencher resulting in an increase
in ﬂuorescence. This assay format has been applied
to DNA adenine-N6 methyltransferase activity (Dam)
(38–40), in all cases the oligonucleotide stem contains
the 50-GATC-30 Dam recognition sequence. The most
recent assay coupled a hemimethylated substrate with
a restriction enzyme (DpnI), which will preferentially
cleave the fully methylated substrate, so that one
methylation event by Dam is reported by a proportional
increase in ﬂuorescence because of DpnI cleavage.
This convenient assay format has the advantage of
providing real-time data, which allows kinetic analysis
of methylation.
We have developed a molecular break light assay for the
continuous measurement of cytosine-C5 methyltransferase
activity in which a partially methylated oligonucleotide
acts as a substrate for cytosine-C5 methylation. The resul-
tant fully methylated oligonucleotide is the optimal
substrate (41) for the cytosine-C5 methylation-speciﬁc
restriction endonuclease GlaI (42). Cleavage of the break
light stem results in separation of the ﬂuorophore and
quencher, resulting in an increase in ﬂuorescence. Using
this assay, we have measured DNMT1 activity and deter-
mined the KDNA
M and KAdoMet




Restriction endonuclease GlaI was purchased from SE
Technologies (Zweibru ¨ cken, Germany), M.SssI and
human DNMT1 were obtained from New England
Biolabs (Herts., UK). Oligonucleotides 1 and 2 for ﬂuo-
rescence assays were purchased from ATDBio
(Southampton, UK). AdoMet and mineral oil (sterile
ﬁltered, mouse embryo tested) were purchased from
Sigma–Aldrich (Poole, UK). GelRed Stain was purchased
from Cambridge Bioscience Limited. Fluorescence mea-
surements were carried out in either 96-well half-area
black ﬂat-bottomed, or 384-well low-volume, hibase
ﬂat-bottomed microplates from Greiner Bio-One Ltd
(Stonehouse, UK). Measurements were taken using a
Tecan Saﬁre 2 microplate reader (Reading, UK). Assays
in 384-well plates were prepared and initiated using a
Beckman Coulter BioMek 3000 liquid handling system,
equipped with a 200-ml single-channel and 20-ml
eight-channel pipette head from Beckman Coulter (High
Wycombe, UK). Data were analysed with the
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Inc., San Jose, CA, USA).
Cytosine-C5 methyltransferase activity assays
The break light oligonucleotide sequences used in










MATAGG(Q) 30, where the
cytosine-C5 methyltransferase recognition sequence is
shown in bold and the GlaI recognition sequence
is underlined, (F) is Cy3 and (Q) is a dabcyl quencher.
Cytosine-C5 methyltransferase activity was measured in
triplicate, in Greiner 384-well plates in a total assay
volume of 20mla t3 7  C unless otherwise stated. All
assays were prepared in buﬀer A, which contained
10mM Tris/HCl pH 7.5, 5mM MgCl2, 1mM DTT, 5%
glycerol, 0.1mg/ml BSA, 20–100mM NaCl and 0–1mM
AdoMet. The 384-well plate assays were prepared by
making an oligonucleotide solution in buﬀer A containing
1.33 the required oligonucleotide concentration. Fifteen
microlitres of this solution was then added to the
microplate per well and the plate equilibrated at 37 C
for 15min. An enzyme solution was prepared on ice, con-
taining GlaI and either additional DNMT1 or M.SssI in
buﬀer A. The assays were initiated by the addition of 5ml
of enzyme solution. Using the same method, 96-well plate
assays were prepared, scaling the volumes up to a total of
100ml per well. Cy3 emission was then measured over time
and for M.SssI methylation reactions the initial rate of
reaction was calculated over the ﬁrst 500s of steady-state
methylation or for DNMT1 experiments, steady-state
rates were measured over the ﬁrst 1000s after the lag
phase. Background ﬂuorescence increase due to
non-speciﬁc oligonucleotide 1 cleavage by GlaI was
accounted for by subtracting a negative control, which
contained GlaI but lacked both DNMT1 and M.SssI.
The rate of ﬂuorescence increase could be converted into
a rate of reaction using a ﬂuorescence calibration curve for
kinetic analysis and the data were ﬁtted to the Michaelis–
Menten equation (43).
Fluorescence was monitored using a Tecan Saﬁre
2
microplate reader, using 10 readings per well for each
measurement and a 0.1s pause between each movement
and reading. The excitation wavelength was 543nm and
the emission wavelength 563nm, with a bandwidth of
5nm for measurements in a 96-well plate, or 7nm for a
384-well plate. The gain setting was 190 for 96-well-plate
measurements and 165 or 133 for 384-well-plate measure-
ments as stated. The Z-position was 9000mm for 96-well
plate and 12500mm for 384-well-plate measurements, with
an integration time of 40ms.
Oligonucleotide 2 calibration curve
Assays containing buﬀer A supplemented with 0mM
AdoMet, 100mM NaCl, 3.56, 4.75, 6.33, 8.43, 11.3, 15.0
and 20nM oligonucleotide 2 and either 0.2 or 1.0U/well
GlaI for 20 (384-well) or 100ml (96-well) assays, respec-
tively. For 100ml assays, ﬂuorescence was measured at a
gain of 190 and for 20ml assays, at gains of 133 and 165.
The endpoint ﬂuorescence values were measured at each
concentration.
Analysis of GlaI activity against oligonucleotides 1 and 2
To conﬁrm the selectivity of GlaI cleavage between the
50-GCGC-30 sequences of partially methylated
oligonucleotide 1 and fully methylated oligonucleotide 2
followed the pattern reported by Tarasova et al. (41),
oligonucleotides 1 or 2 (10mM) were incubated with
GlaI (8U) for 1h and then analysed by urea-PAGE.
The eﬀect of oligonucleotide 1 concentration upon GlaI
activity was measured in a series of activity assays in
buﬀer A supplemented with 50mM AdoMet, 100mM
NaCl, 2.4U/well GlaI and 0.028, 0.047, 0.078, 0.13,
0.22, 0.36, 0.6 and 1mM oligonucleotide 1. The depen-
dence of rate upon concentration of the fully methylated
oligonucleotide 2 was measured in a series of activity
assays containing 50mM AdoMet, 100mM NaCl,
0.05U/well GlaI and 0.028, 0.047, 0.078, 0.13, 0.22, 0.36
and 0.6mM oligonucleotide 2.
Analysis of reproducibility and non-speciﬁc cleavage by
GlaI in coupled M. SssI assays
To analyse reproducibility, a coupled M.SssI assay was
repeated six times under standard assay conditions at
the following ﬁnal concentrations: 1mM oligonucleotide
1,5 0 mM Adomet, 10nM M.SssI and 2.4U/well GlaI in
buﬀer A in two independent experiments. The background
ﬂuorescence increase due to non-speciﬁc cleavage of
oligonucleotide 1 by GlaI was determined by comparing
complete assays containing M.SssI and GlaI (in the
column labelled ‘assay’ in Table 2) with a negative
control containing only GlaI (Table 2, ‘negative
control’). Background cleavage of partially methylated
oligonucleotide 1 by GlaI was calculated as a percentage
of the complete assay signal (i.e. negative control signal
divided by assay signal).
Comparison of stepwise methylation and restriction
reactions with the coupled activity assay
Stepwise assays comprised of 20ml of buﬀer A supple-
mented with 250nM oligonucleotide 1 and 10nM
M.SssI and 100mM NaCl. Triplicate methylation reac-
tions were initiated with 10mM AdoMet at eight time
points and incubated at 37 C for 0, 1, 2, 4, 8, 16, 32 and
64min. Triplicate control assays were also prepared con-
taining no AdoMet and incubated under the same condi-
tions. Reactions were stopped by heat denaturation and
then cooled on ice. The resultant solutions were then
equilibrated at 37 C for 5min in a black, ﬂat-bottomed,
low-volume, 384-well Greiner microplate and the cleavage
reactions were then initiated by the addition of 2.4U/well
GlaI. Subsequent ﬂuorescence increases due to separation
of ﬂuorophore and quencher were monitored in a Tecan
Saﬁre
2 microplate reader until an endpoint was reached.
Coupled activity assays containing M.SssI and GlaI were
prepared in triplicate as described previously and con-
tained the same substrate and enzyme concentrations as
the stepwise assays. The ﬂuorescence of the coupled assays
was monitored over 64min. Negative control rates
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complete assays and ﬂuorescence changes for both the
stepwise and the coupled assays were converted to frac-
tional turnover, calculated for each time point as (ﬂuores-
cence signal/maximum change in ﬂuorescence) to facilitate
comparison. After GlaI-mediated cleavage of methylated
oligonucleotide 1, assays were analysed by 20%
Urea-PAGE. The resultant gel was visualized on a
Bio-Rad Molecular Imager Gel Doc XR+ system using
the trans-UV mode before and after staining with GelRed
stain.
Catalytic DNMT1 activity assay
DNMT1 activity was assayed in duplicate in 96-well
half-area black ﬂat-bottomed microplates. The assay
volume was 100ml; assays were incubated at 37 C for 8h
and measurements were taken every 145s. Assays con-
tained 30nM oligonucleotide 1, 25mM NaCl, 1mM
AdoMet, 2.8nM DNMT1 and 0.8U/well GlaI in buﬀer
A. Wells were covered with 5ml mineral oil to minimize
evaporation.
Eﬀect of increasing oligonucleotide concentration upon
DNMT1 activity
The eﬀect of the variation of oligonucleotide concentra-
tion upon DNMT1 activity was assayed in duplicate at a
gain of 165, in buﬀer A containing 50mM NaCl, 1mM
AdoMet and 30, 60, 120 and 240nM oligonucleotide 1.
The DNMT1 concentration was 2.8nM and the GlaI con-
centration was 0.2U/well.
Determination of the optimal GlaI concentration for the
kinetic analysis of M.SssI activity
The concentration of GlaI required for kinetic analysis of
M.SssI was determined in experiments containing buﬀer A
supplemented with 1mM oligonucleotide 1,5 0 mM
AdoMet, 100mM NaCl, 10nM M.SssI and GlaI concen-
trations of 0, 0.2, 0.4, 0.8, 1.2, 1.6, 2.4 and 3.2U/well at a
gain setting of 133.
Kinetic analysis of M.SssI activity
For kinetic analysis, M.SssI was assayed at a gain setting
of 133 in buﬀer A in each case containing 100mM NaCl,
10nM M.SssI and 2.4U/well GlaI. The dependence of
M.SssI activity upon the concentration of oligonucleotide
1 was measured in a series of assays additionally contain-
ing 50mM AdoMet and 0.028, 0.047, 0.078, 0.13, 0.22,
0.36, 0.6 and 1mM concentrations of oligonucleotide 1.
The eﬀect of AdoMet concentration upon M.SssI
activity was measured in assays additionally containing
1mM oligonucleotide 1 and AdoMet concentrations of
0.28, 0.47, 0.78, 1.3, 2.16, 3.6, 6 and 10mM.
RESULTS
Assay design
To enable the continuous measurement of cytosine-C5
methyltransferase activity, an oligonucleotide
(oligonucleotide 1) was used which lacks cytosine
methylation at a single site out of a possible four within
the sequence. We have termed this the (n-1) strategy,
where n is the number of methylated bases required for
the oligonucleotide to become the optimal substrate for a
methylation-sensitive restriction endonuclease. It allows
the coupling of a single methylation event by
a methyltransferase to a proportional increase in ﬂuores-
cence. In this case, the optimal restriction site for GlaI, a
5-methylcytosine-speciﬁc endonuclease is the palindromic
sequence 50-GC
MGC
M-30 and so n=4. Oligonucleotide 1
therefore contains three 5-methylcytosines, leaving a
single site available for methylation. In the assay,
methylation of oligonucleotide 1 forms the tetra
methylated product oligonucleotide 2. In situ GlaI restric-
tion of fully methylated 2 leads to the separation of
ﬂuorophore and quencher with a resultant proportional
increase in ﬂuorescence (Figure 1).
Calibration of oligonucleotide ﬂuorescence
Calibration curves were used to convert ﬂuorescence mea-
surements from real-time assays into a concentration of
cleaved fully methylated oligonucleotide 2. The concentra-
tion of oligonucleotide 2 was varied between 3.56 and
20nM and endpoint ﬂuorescence values were ﬁtted to a
linear function (Supplementary Figure S1). The gradient
of each ﬁt and the measures of goodness of ﬁt to a linear
function (R
2) are shown in Table 1.
Figure 1. Break light cytosine-C5 methyltransferase activity assay.
The ﬂuorescence of the hemimethylated oligonucleotide 1 is quenched
by the dabcyl group. It is a substrate for cytosine-C5 methyltransferases
such as DNMT1 or M.SssI and upon methylation yields the fully
methylated oligonucleotide 2, which is cleaved by GlaI, separating
the ﬂuorophore from the quencher and resulting in an increase in
ﬂuorescence, which is proportional to the concentration of
oligonucleotide 3.
Table 1. Oligonucleotide 2 ﬂuorescence calibration curve data
Assay volume (ml) Gain Gradient (AU/nM) R
2
20 133 183±7.1 0.990
20 165 1347±29 0.997
100 190 962±50 0.982
R
2 is a measure of the goodness of ﬁt to a linear function.
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cleavage by GlaI
Partially and fully methylated oligonucleotides 1 and 2
were incubated with GlaI and then analysed by
urea-PAGE (Figure 2). The experiment conﬁrmed the
selectivity of GlaI for the tetramethylated substrate as
originally reported by Tarasova et al. (41). In a further
experiment, the signal from background cleavage of par-
tially methylated oligonucleotide 1 by GlaI over a concen-
tration range of 0.03–1mM was calculated as a percentage
of the complete assay signal (Table 2). The data show that
non-speciﬁc cleavage by GlaI accounts for  10–15% of
the overall assay signal and thus does not have a substan-
tial eﬀect on the quality of the results.
The reproducibility of the assay was investigated by
determining the standard deviation and the coeﬃcient of
variation (CV) in rate of ﬂuorescence change for six iden-
tical assays and negative control assays (lacking M.SssI)
under standard conditions. The average negative control
signal was found to be very low at 2.7±2.7% of the assay
signal. The assay signal was found to be highly reproduc-
ible with an average of 21.2±1.2AU/s, giving a CV
of 4.5%.
Kinetic analysis of GlaI activity
The rate of cleavage of the partially methylated substrate
oligonucleotide 1 by GlaI must be suﬃciently slow to
allow satisfactory diﬀerentiation between the ﬂuorescence
signal observed due to background cleavage of partially
methylated oligonucleotide 1 and that caused by cleavage
of fully methylated oligonucleotide 2. The optimal NaCl
and MgCl2 concentrations for GlaI selectivity were deter-
mined in a simple experiment in which the concentrations
of NaCl (0–200mM) and MgCl2 (1–20mM) were varied
(Supplementary Figure S2) and this was identiﬁed as
100mM NaCl and 5mM MgCl2. The eﬀect of the NaCl
concentration on DNMT1 activity was analysed to ensure
these conditions were appropriate (Supplementary Figure
S3). The break light assay was used to determine KDNA
M
of GlaI for oligonucleotide 1 (Figure 3A) and
oligonucleotide 2 (Figure 3B). The dependence of GlaI
activity upon oligonucleotide concentration was ﬁtted to
the Michaelis–Menten equation. The KDNA
M for
oligonucleotide 1 was observed to be 236±23nM and
the Vmax to be 0.100±0.004fmol/U/s; in comparison,
for oligonucleotide 2, the KDNA
M was 44.8±11nM
and the Vmax was 28.5±1.8fmol/U/s. The relative speciﬁ-
city constant [deﬁned as Vmax/KM (44)] for oligonucleotide
1 is 4.2 10
–10U
–1s




–1, which indicates that GlaI shows a
considerable preference for the fully methylated
oligonucleotide 2. This preference is highly advantageous
in our coupled assay format, as the restriction enzyme
must selectively cleave the fully methylated oligonucleo-
tide 2 in the presence of a relatively high concentration
of the partially methylated methyltransferase oligo-
nucleotide 1.
Comparison of stepwise methylation and restriction
reactions with the coupled activity assay
To ensure the ﬂuorescence signal from the coupled assay
was accurately reﬂecting the degree of substrate
methylation, the coupled assay was compared with a
Figure 2. Urea-PAGE analysis of partially and fully methylated oligonucleotides incubated with GlaI. Partially methylated oligonucelotide 1 or fully
methylated oligonucleotide 2 (10mM) were incubated with GlaI (8 U) for 1h. (A) Fluorescence image. (B) White light image. Lanes: M,
oligonucleotide ladder (bases); lane 1, oligonucleotide 1; lane 2, GlaI treated oligonucleotide 1; lane 3, oligonucleotide 2; lane 4, GlaI-treated
oligonucleotide 2.









0.03 3.33 0.47 14.1
0.05 4.07 0.38 9.34
0.08 5.36 0.59 11.0
0.13 7.53 0.88 11.7
0.22 10.4 1.25 12.0
0.36 14.3 1.48 10.4
0.60 18.4 1.64 8.91
1.00 21.8 0.30 1.38
Assays contained oligonucleotide 1, AdoMet, M.SssI and GlaI.
Negative control assays were prepared identically except that they
lacked M.SssI. Background cleavage was calculated as the percentage
of assay signal caused by non-speciﬁc cleavage of partially methylated
oligonucleotide 1 by GlaI.
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tions were carried out by independent steps. The results of
this experiment are shown in Figure 4. For the time
course, the methylation reactions were stopped by heat
denaturation of the methyltransferase at selected time
points, then in a second step, the cooled samples were
restricted with GlaI and the ﬂuorescent signal monitored
until an endpoint was reached. These endpoint ﬂuores-
cence readings were converted to fractional turnover (ﬂu-
orescence/maximum ﬂuorescence) and plotted against the
average of three coupled assays (Figure 4A). The time
course of stepwise activity assays, a sample of the
coupled assay at the endpoint (64min) and appropriate
controls were analysed by urea PAGE (Figure 4B and
C). The results of this gel analysis show the cleaved, ﬂuo-
rescent product (7bp) increasing with time and no
cleavage in the negative controls (no AdoMet) and are
in good agreement with the ﬂuorescence measurements
shown in Figure 4A.
Analysis of DNMT1 activity using the molecular break
light assay
DNMT1 activity was measured over a time period of 8h
using the 14bp stem oligonucleotide 1 at concentration of
30nM as a substrate and a DNMT1 concentration of
2.8nM. A plot of the real-time ﬂuorescence data against
time for the assay and negative control (containing no
DNMT1) shows that, whilst the ﬂuorescence due to back-
ground cleavage decreases slowly over the course of the
assay, the ﬂuorescence due to cleavage of the DNMT1
methylation product oligonucleotide 2 continues to
increase (Figure 5A). During this assay, DNMT1 was
observed to maintain a roughly linear activity for 8h,
with no apparent burst phase (Figure 5A). After subtrac-
tion of the background signal (Figure 5B), the ﬂuores-
cence increase can be ﬁtted to a linear function
(goodness of ﬁt, R
2=0.99) allowing the steady-state rate
to be determined as 0.83±0.07pmol/mg/s from a set of
duplicate assays. The total change in ﬂuorescence during
this assay corresponds to the turnover of 1.18±0.06pmol
of substrate oligonucleotide, which is 39.3% of the initial
substrate concentration and equates to 4.2±0.2 turn-
overs of DNMT1.
The dependence of DNMT1 activity upon oligonucleotide
concentration
The eﬀect of increasing oligonucleotide concentration
upon the observed steady state rate was investigated in a
series of assays containing 30–240nM oligonucleotide 1
and 2.8nM DNMT1. At each DNA concentration, a
short lag phase was observed (Figure 6A). Such lag
phases are commonly observed in coupled enzyme
assays (45) and in this case may correspond to the time
taken for the concentration of fully methylated
oligonucleotide 2 to reach a steady-state concentration.
Plotting the steady-state rates against concentration of
oligonucleotide 1 gives a roughly proportional linear
increase in rate (Figure 6B). The maximum observed
rate of oligonucleotide 1 turnover by DNMT1 was
2.97±0.27h
–1 at a substrate DNA concentration of
240nM. The rate of background cleavage of
oligonucleotide 1 by GlaI at each concentration was
low, but increases slightly with increasing oligonucleotide
concentration. This experiment demonstrates the advan-
tage of GlaI having a high speciﬁcity for the
oligonucleotide 2 over oligonucleotide 1, as the back-
ground cleavage is very slow even at relatively high
substrate concentrations.
Determination of the optimal GlaI concentration for the
kinetic analysis of M.SssI activity
M.SssI was utilized as a model methyltransferase to test
the application of the break light assay for kinetic analysis
of cytosine-C5 methylation. To ensure that the rate of
ﬂuorescence increase was not limited by GlaI concentra-
tion at high (1mM) DNA concentrations, a set of assays
were prepared in which GlaI concentration was varied
(0–3.2U/well) and oligonucleotide 1 (1mM), M.SssI
(10nM) and AdoMet (50mM) concentrations were ﬁxed.
The concentration of DNA was over twice that required
Figure 3. Dependence of GlaI activity on oligonucleotide concentration. (A) Using partially methylated oligonucleotide 1 as the substrate and (B)
using fully methylated oligonucleotide 2 as the substrate.
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at Vmax. The observed rate of methylation was then
plotted against GlaI concentration (Figure 7). Increasing
concentrations of GlaI resulted in an increase in the
observed initial rate of product formation up to a concen-
tration of 1.6U/well. Further increases in GlaI concentra-
tion did not result in a signiﬁcant increase in the reaction
rate and a concentration of 2.4U/well GlaI was selected
for the kinetic analysis of M.SssI activity, to ensure that
the observed rate of ﬂuorescence increase reﬂects the rate
of methylation.
Kinetic analysis of M.SssI activity
The break light assay was used to determine KDNA
M
(oligonucleotide 1) and KAdoMet
M for M.SssI. In the
activity assays (Figure 8A), a slowing of the rate of ﬂuo-
rescence change were observed in the initial phase (up to
 100s), but this was followed by a stable steady-state
phase (up to 600s), which was used to determine the
reaction rates. The source of the variation in rate during
the initial phase is at present unknown: some of the possi-
ble factors might include temperature equilibration of the
plate, mixing of the wells or rate-limiting product release,
resulting in a burst phase. For both substrates, the depen-
dence of M.SssI activity upon substrate concentration
was ﬁtted to the Michaelis–Menten equation. KDNA
M was
found to be 234±36nM (Figure 8B), which compares
well with the value of 180nM reported previously (46)
for a 30-bp hemimethylated oligonucleotide, although
for an alternative sequence of the same length, M.SssI
showed a signiﬁcantly higher KDNA
M of 1.6mM (47).
Using our assay, KAdoMet
M for M.SssI was measured to be
675±110nM (Figure 8C). The literature values for
KAdoMet
M are 50nM (46) and 2.2mM (48) and may depend
on the precise assay conditions used; however, the value
determined using our assay falls between these two. The
range of values calculated for kcat, from data shown in
Figures 7, 8B and C are 0.98±0.02, 0.73±0.03 and
0.49±0.02 turnovers/min, respectively. These values are
similar to the reported kcat for the protein of 0.16 turn-
overs/min (46).
DISCUSSION
The cytosine-C5 methyltransferase assay reported herein
is the ﬁrst to permit continuous monitoring of cytosine
methylation. This has been achieved using an (n-1) molec-
ular break light assay, in which a single methylation event
forms the optimal GlaI restriction endonuclease substrate,
which is cleaved in situ resulting in a proportional increase
in ﬂuorescence. The reproducibility, sensitivity and
relative background cleavage were all within the range
that indicates the assay is suitable for the analysis of
cytosine-C5 methyltranferases. Validation of the coupled
assay format has been achieved by comparing the contin-
uous coupled assay to a stopped time-course experiment,
in which the methylation and cleavage reactions were
carried out in separate steps. This experiment shows that
both methods give comparable results whilst also
demonstrating the greater level of information it is
possible to obtain from the real-time assay. An appropri-
ate concentration of magnesium chloride and a suitable
ionic strength have been identiﬁed to permit the normal
functioning of both the methyltransferase and the restric-
tion enzyme.
We have utilized this assay format for the analysis of
DNMT1 activity. In an assay containing 30nM
oligonucleotide substrate a linear increase in methylation
Figure 4. Analysis of time courses for coupled and stepwise enzymatic
reactions. (A) Comparison of time courses of product formation in
stepwise (ﬁlled circles) and coupled (solid line) assays expressed as frac-
tional turnover. (B) Gel analysis of coupled and stepwise enzymatic
reactions. The ﬂuorescence image is of a 20% urea-polyacrylamide
gel of stepwise and coupled assays and was recorded before staining.
Lanes were as follows: 1, coupled assay negative control (no AdoMet);
2, stepwise assay negative control (no AdoMet) incubated for 0min; 3,
stepwise assay negative control (no AdoMet) incubated for 64min;
4-11, stepwise assay incubated for 0, 1, 2, 4, 8, 16, 32 and 64min
respectively; 12, coupled assay. (C) As in (B) but after staining with
GelRed stain.
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The ability to sustain methylation over an extended period
depends upon the NaCl concentration; below 50mM, a
linear rate over extended periods of up to 8h is
observed, whereas at higher concentrations of up to
100mM, the length of this linear phase is reduced. This
observation is consistent with the reported reduction of
DNMT1 activity at salt concentrations over 50mM (49).
There is a slight decrease in selectivity of GlaI for
oligonucleotide substrate 2 over 1 at lower NaCl concen-
tration; however, even under these conditions, the rate of
background cleavage of 1 remained very low.
The observation of a constant rate of methylation of
partially methylated oligonucleotide 1 over four turnovers
implies that in our assay, DNMT1 does not exhibit burst
phase kinetics as reported for other hemimethylated
50-CG-30 oligonucleotides (47), but the observed activity
more closely mirrors the de novo DNMT1 activity
observed when unmethylated DNA is the substrate (50).
Figure 6. Eﬀect of increasing oligonucleotide 1 concentration on DNMT1 activity. (A) Real-time data averaged from duplicate
assays. Assays contained oligonucleotide 1 at concentrations of 30nM (black line), 60nM (orange line), 120nM (green line) and 240nM
(blue line) with associated negative controls (lacking DNMT1) shown as dotted lines. (B) Plot of steady-state rate against concentration of
oligonucleotide 1.
Figure 5. Activity of DNMT1 with oligonucleotide 1.( A) Comparison of ﬂuorescence changes in a full assay (solid black line) and a negative control
assay lacking DNMT1 (dotted line). (B) Plot of change in the concentration of oligonucleotide 3 after background subtraction.
Figure 7. Eﬀect of GlaI concentration on the observed activity of
M.SssI using oligonucleotide 1 as a substrate.
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oligonucleotide substrate 1 is not suﬃciently long to
interact with the N-terminal regulatory domain and may
not be subject to the complex allosteric control that has
been proposed for DNMT1 (50). The activity assay
appears to function with hairpin oligonucleotides contain-
ing a complimentary stem as short as 14bp, but the
oligonucleotides previously used as DNMT1 substrates
in kinetic analysis were 30–36bp in length (50,51) and
extension of oligonucelotide 1 may yield a better model
substrate. At a concentration of 240nM oligonucleotide 1,
the observed rate of DNMT1 turnover was estimated to
be 2.97±0.27h
–1, which is comparable to other reported
activities against 50-CG-30 hemimethylated substrates of
3.0h
–1 (52).
A linear relationship was observed between DNMT1
activity and oligonucleotide concentration; however, at
all concentrations of DNA a lag phase was observed
before the linear steady-state rate of reaction was
reached (Figure 6A). A lag phase has previously been
reported in experiments with DNMT1 and an
unmethylated substrate and is observed to increase with
the concentration of DNA, although it is not clear that the
lag phases are the result of identical processes. It may be
that the lag phase observed in our assay arises from the
time taken for the concentration of fully methylated
oligonucleotide 2 to reach a steady-state concentration.
If this were the case, then the addition of higher concen-
trations of GlaI would minimize the lag phase. However,
the non-speciﬁc cleavage of oligonucleotide 1 is minimized
by adding the smallest possible amount of GlaI.
Therefore, a compromise concentration of GlaI was
required, which gave an acceptable lag phase and a toler-
able level of GlaI-dependent background cleavage of
oligonucleotide 1.
The suitability of the assay for the kinetic analysis of
cytosine-C5 methylation was tested by the kinetic charac-
terization of the bacterial cytosine-C5 methyltransferase
M.SssI. The kinetic constants measured for M.SssI using
our assay were comparable to those reported in the liter-
ature (46,47) conﬁrming the validity of the assay for the
kinetic analysis of cytosine-C5 methylation. The underly-
ing cause of the decrease in apparent reaction rates
observed in the ﬁrst  100s of the M.SssI assays is not
known, but reaction rates were determined using data
from the steady-state region, which occurred between
 100 and 600s.
In the case of the DNMT1 methylation reaction, even at
the highest DNA concentration (240nM), the reaction
had progressed to 0.18% of completion in 1000s and in
the fastest observed M.SssI reaction only 5.5% conversion
had been achieved after 600s. This relatively low level of
turnover allowed the reaction rates observed to be treated
purely as initial rates of reaction, if it is assumed that the
GlaI substrate concentration remains essentially constant
for both methyltransferase and restriction enzyme a direct
background subtraction can be made. It is therefore rela-
tively simple to account for the slight increase in ﬂuores-
cence observed due to non-speciﬁc GlaI activity and
obtain accurate rate data.
This strategy for the analysis of cytosine-C5
methyltransferase activity has a number of practical
advantages. It provides the ﬁrst real-time assay for
cytosine-C5 methyltransferase activity, which results in a
ﬂuorescence increase that is directly proportional to
substrate methylation, greatly facilitating kinetic
analysis. This has been demonstrated using M.SssI and
DNMT1 and provides a convenient alternative to the
Figure 8. Kinetic analysis of M.SssI activity. (A) Background-
subtracted raw data showing the ﬁrst 600s for methylation of
oligonucleotide 1 by M.SssI. The concentration of oligonucleotide 1
increases from lowest to highest as follows: 28, 47, 78, 130, 220, 360,
600 and 1000nM. (B) Dependence of M.SssI activity on oligonucleotide
concentration. (C) Dependence of M.SssI activity on AdoMet
concentration.
PAGE 9 OF 11 Nucleic Acids Research,2010, Vol.38, No. 9 e107radioactive ﬁlter-binding assay for this purpose. This
simple and practically robust assay is suitable for high-
throughput analysis of DNMT1 activity and is likely to
provide an eﬃcient method for screening large compound
libraries for DNMT1 inhibitors.
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